Location History:
- Pulheim, DE (2003)
- Brookline, MA (US) (2002 - 2010)
- Cologne, DE (2010)
Company Filing History:
6 out of 1,210 
1 out of 1,745 
1 out of 818 
Years Active: 2002-2010
Title: Innovator in Cancer Research - Joachim L. Schultze
Introduction
Joachim L. Schultze, based in Brookline, MA, is a distinguished inventor known for his contributions to cancer research and immunotherapy. With a total of six patents to his name, Schultze has taken significant strides in the field of oncology, focusing on innovative therapeutic and diagnostic methods.
Latest Patents
One of Schultze's latest patents revolves around cancer immunotherapy and diagnosis using universal tumor-associated antigens, including hTERT. This groundbreaking invention outlines methods for utilizing universal tumor-associated antigens, particularly the telomerase catalytic subunit (hTERT), to conduct immunotherapy and enable accurate cancer diagnosis.
Another notable patent relates to isolated nucleic acids encoding novel CD100 molecules. These CD100 molecules are instrumental in stimulating a leukocyte response, specifically affecting B cell responses like aggregation, differentiation, survival, and T cell proliferation. The patent details isolated nucleic acids, antisense nucleic acids, recombinant expression vectors, and host cells for the expression of these critical molecules. Moreover, it encompasses the development of diagnostic and therapeutic methods employing these innovative compositions.
Career Highlights
Throughout his career, Joachim Schultze has collaborated with prestigious institutions such as Dana-Farber Cancer Institute Inc. and Institut National De La Santé et de la Recherche Médicale. His affiliations with these organizations have greatly enhanced his research capabilities and helped bridge the gap between laboratory discoveries and clinical applications.
Collaborations
Schultze has had the opportunity to work alongside esteemed colleagues including Lee M. Nadler and Gordon James Freeman. These collaborations have fostered an environment of innovation and multidisciplinary research, essential for advancing the understanding of cancer and developing effective therapies.
Conclusion
Joachim L. Schultze’s impressive record of patents and his dedicated work in cancer immunotherapy solidify his status as a significant figure in the field of medical innovations. His research not only paves the way for new diagnostic techniques but also enhances the therapeutic landscape for patients battling cancer.